Advaxis, Inc. (ADXS) Expected to Post FY2019 Earnings of ($2.45) Per Share

Advaxis, Inc. (NASDAQ:ADXS) – Stock analysts at Jefferies Group issued their FY2019 earnings per share estimates for Advaxis in a report issued on Thursday. Jefferies Group analyst B. Amin expects that the biotechnology company will earn ($2.45) per share for the year. Jefferies Group also issued estimates for Advaxis’ FY2020 earnings at ($0.86) EPS and FY2021 earnings at $1.29 EPS.

A number of other equities research analysts also recently commented on the stock. BidaskClub upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a report on Saturday, September 9th. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Advaxis in a report on Wednesday, November 8th. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $19.00 price target on shares of Advaxis in a report on Monday, September 25th.

Shares of Advaxis (NASDAQ ADXS) traded up $0.04 during midday trading on Monday, hitting $3.00. 913,200 shares of the stock were exchanged, compared to its average volume of 699,413. The stock has a market capitalization of $124.86, a P/E ratio of -1.30 and a beta of 1.95. Advaxis has a 1-year low of $2.71 and a 1-year high of $10.06.

Advaxis (NASDAQ:ADXS) last posted its earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The business had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million.

In related news, insider Robert Petit sold 12,625 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,273.75. Following the sale, the insider now directly owns 237,265 shares of the company’s stock, valued at $756,875.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $4.30, for a total transaction of $2,580,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,872,291 shares of company stock valued at $8,163,810. Insiders own 7.21% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its position in Advaxis by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock valued at $840,000 after buying an additional 817 shares in the last quarter. Wells Fargo & Company MN lifted its position in Advaxis by 2.6% during the second quarter. Wells Fargo & Company MN now owns 44,813 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 1,144 shares in the last quarter. Rhumbline Advisers lifted its position in Advaxis by 3.7% during the second quarter. Rhumbline Advisers now owns 42,508 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 1,530 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in Advaxis by 2.4% during the second quarter. TIAA CREF Investment Management LLC now owns 98,164 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 2,329 shares in the last quarter. Finally, Northern Capital Management LLC lifted its position in Advaxis by 14.6% during the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 2,650 shares in the last quarter. 41.90% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Advaxis, Inc. (ADXS) Expected to Post FY2019 Earnings of ($2.45) Per Share” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/25/advaxis-inc-adxs-expected-to-post-fy2019-earnings-of-2-45-per-share.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply